Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03295240 · ClinicalTrials.gov registry record · Early Phase 1
The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma
A Early Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
NCT03295240: Completed Early Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03295240 is a Early Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03295240, a Early Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety of Venetoclax in combination with FDA approved treatments Bendamustine, Rituximab and Ibrutinib (BR-I). This study will examine the effects Venetoclax has on participants when it is given in combination with BR-I.
Interventions
- DRUG BR-I (bendamustine, rituximab, ibrutinib)
- DRUG VEN (Venetoclax)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2017-09-20 |
| Est. Completion | 2024-01-22 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03295240
The ClinicalTrials.gov registry entry for NCT03295240 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BR-I (bendamustine, rituximab, ibrutinib) is the first listed.
NCT03295240 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03295240 about?
NCT03295240 is a clinical study titled "The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma". The purpose of this study is to test the safety of Venetoclax in combination with FDA approved treatments Bendamustine, Rituximab and Ibrutinib (BR-I). This study will examine the effects Venetoclax has on participants when it is given in combination with BR-I.
What is the current status of trial NCT03295240?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2017-09-20. Estimated completion is 2024-01-22.
What interventions are being tested in trial NCT03295240?
The interventions under investigation include: BR-I (bendamustine, rituximab, ibrutinib) (DRUG), VEN (Venetoclax) (DRUG).
Who is sponsoring clinical trial NCT03295240?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.